Cargando…

Self-injected contraceptives: does the investment reflect women’s preferences?

Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) is an innovative contraceptive method aimed at meeting women’s unique circumstances and needs, largely due to its ability to be self-injected. Substantial research and advocacy investments have been made to promote roll-out of DMPA-SC across s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Shannon N., Magalona, Sophia, Zimmerman, Linnea A., OlaOlorun, Funmilola, Omoluabi, Elizabeth, Akilimali, Pierre, Guiella, Georges, Gichangi, Peter, Anglewicz, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289037/
https://www.ncbi.nlm.nih.gov/pubmed/35835480
http://dx.doi.org/10.1136/bmjgh-2022-008862
_version_ 1784748574281564160
author Wood, Shannon N.
Magalona, Sophia
Zimmerman, Linnea A.
OlaOlorun, Funmilola
Omoluabi, Elizabeth
Akilimali, Pierre
Guiella, Georges
Gichangi, Peter
Anglewicz, Philip
author_facet Wood, Shannon N.
Magalona, Sophia
Zimmerman, Linnea A.
OlaOlorun, Funmilola
Omoluabi, Elizabeth
Akilimali, Pierre
Guiella, Georges
Gichangi, Peter
Anglewicz, Philip
author_sort Wood, Shannon N.
collection PubMed
description Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) is an innovative contraceptive method aimed at meeting women’s unique circumstances and needs, largely due to its ability to be self-injected. Substantial research and advocacy investments have been made to promote roll-out of DMPA-SC across sub-Saharan Africa. To date, research on the demand for DMPA-SC as a self-injectable method has been conducted largely with healthcare providers, via qualitative research, or with highly specific subsamples that are not population based. Using three recent rounds of data from Performance Monitoring for Action, we examined population-representative trends in demand, use, and preference for self-injection among current non-users in Burkina Faso, the Democratic Republic of Congo (Kinshasa and Kongo Central regions), Kenya, and Nigeria (Lagos and Kano States). We found that while over 80.0% of women had heard of injectables across settings, few women had heard of self-injection (ranging from 13.0% in Kenya to 24.8% in Burkina Faso). Despite initial increases in DMPA-SC prevalence, DMPA-SC usage began to stagnate or even decrease in all settings in the recent three years (except in Nigeria-Kano). Few (0.0%–16.7%) current DMPA-SC users were self-injecting, and the majority instead were relying on a healthcare provider for administration of DMPA-SC. Among current contraceptive non-users wishing to use an injectable in the future, only 1.5%–11.4% preferred to self-inject. Our results show that self-injection is uncommon, and demand for self-injection is very limited across six settings, calling for further qualitative and quantitative research on women’s views on DMPA-SC and self-injection and, ultimately, their contraceptive preferences and needs.
format Online
Article
Text
id pubmed-9289037
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-92890372022-08-01 Self-injected contraceptives: does the investment reflect women’s preferences? Wood, Shannon N. Magalona, Sophia Zimmerman, Linnea A. OlaOlorun, Funmilola Omoluabi, Elizabeth Akilimali, Pierre Guiella, Georges Gichangi, Peter Anglewicz, Philip BMJ Glob Health Analysis Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) is an innovative contraceptive method aimed at meeting women’s unique circumstances and needs, largely due to its ability to be self-injected. Substantial research and advocacy investments have been made to promote roll-out of DMPA-SC across sub-Saharan Africa. To date, research on the demand for DMPA-SC as a self-injectable method has been conducted largely with healthcare providers, via qualitative research, or with highly specific subsamples that are not population based. Using three recent rounds of data from Performance Monitoring for Action, we examined population-representative trends in demand, use, and preference for self-injection among current non-users in Burkina Faso, the Democratic Republic of Congo (Kinshasa and Kongo Central regions), Kenya, and Nigeria (Lagos and Kano States). We found that while over 80.0% of women had heard of injectables across settings, few women had heard of self-injection (ranging from 13.0% in Kenya to 24.8% in Burkina Faso). Despite initial increases in DMPA-SC prevalence, DMPA-SC usage began to stagnate or even decrease in all settings in the recent three years (except in Nigeria-Kano). Few (0.0%–16.7%) current DMPA-SC users were self-injecting, and the majority instead were relying on a healthcare provider for administration of DMPA-SC. Among current contraceptive non-users wishing to use an injectable in the future, only 1.5%–11.4% preferred to self-inject. Our results show that self-injection is uncommon, and demand for self-injection is very limited across six settings, calling for further qualitative and quantitative research on women’s views on DMPA-SC and self-injection and, ultimately, their contraceptive preferences and needs. BMJ Publishing Group 2022-07-14 /pmc/articles/PMC9289037/ /pubmed/35835480 http://dx.doi.org/10.1136/bmjgh-2022-008862 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Analysis
Wood, Shannon N.
Magalona, Sophia
Zimmerman, Linnea A.
OlaOlorun, Funmilola
Omoluabi, Elizabeth
Akilimali, Pierre
Guiella, Georges
Gichangi, Peter
Anglewicz, Philip
Self-injected contraceptives: does the investment reflect women’s preferences?
title Self-injected contraceptives: does the investment reflect women’s preferences?
title_full Self-injected contraceptives: does the investment reflect women’s preferences?
title_fullStr Self-injected contraceptives: does the investment reflect women’s preferences?
title_full_unstemmed Self-injected contraceptives: does the investment reflect women’s preferences?
title_short Self-injected contraceptives: does the investment reflect women’s preferences?
title_sort self-injected contraceptives: does the investment reflect women’s preferences?
topic Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289037/
https://www.ncbi.nlm.nih.gov/pubmed/35835480
http://dx.doi.org/10.1136/bmjgh-2022-008862
work_keys_str_mv AT woodshannonn selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT magalonasophia selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT zimmermanlinneaa selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT olaolorunfunmilola selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT omoluabielizabeth selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT akilimalipierre selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT guiellageorges selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT gichangipeter selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences
AT anglewiczphilip selfinjectedcontraceptivesdoestheinvestmentreflectwomenspreferences